Brokerages Set Savara Inc. (NASDAQ:SVRA) Price Target at $10.14

Shares of Savara Inc. (NASDAQ:SVRA) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $10.1429.

SVRA has been the topic of several analyst reports. William Blair set a $10.00 target price on Savara in a research report on Monday, March 16th. Oppenheimer assumed coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th.

Savara Stock Performance

NASDAQ SVRA opened at $6.21 on Friday. The company has a fifty day simple moving average of $5.37 and a 200 day simple moving average of $5.56. Savara has a 12-month low of $2.23 and a 12-month high of $7.01. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.27 billion, a P/E ratio of -11.09 and a beta of 0.24.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Sell-side analysts predict that Savara will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers increased its position in shares of Savara by 10.8% during the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after acquiring an additional 16,634 shares during the last quarter. Prudential Financial Inc. purchased a new position in Savara in the second quarter worth $30,000. XTX Topco Ltd bought a new position in Savara in the 2nd quarter valued at $201,000. Invesco Ltd. grew its stake in Savara by 35.4% in the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after purchasing an additional 31,633 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.